|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on August 29, 2002; DOI 10.1182/blood-2002-01-0189.
NEOPLASIA
From the 3rd Department of Medicine, Technical
University of Munich, Munich, Germany.
In B-cell chronic lymphocytic leukemia (B-CLL), malignant
cells seem to be arrested in the G0/early G1
phase of the cell cycle, and defective apoptosis might be involved in
disease progression. However, increasing evidence exists that
B-CLL is more than a disease consisting of slowly accumulating resting
B cells: a proliferating pool of cells has been described in lymph
nodes and bone marrow and might feed the accumulating pool in the
blood. Rapamycin has been reported to inhibit cell cycle progression in
a variety of cell types, including human B cells, and has shown
activity against a broad range of human tumor cell lines. Therefore, we
investigated the ability of rapamycin to block cell cycle progression
in proliferating B-CLL cells. We have recently demonstrated
that stimulation with CpG-oligonucleotides and interleukin-2 provides a
valuable model for studying cell cycle regulation in malignant B cells.
In our present study, we demonstrated that rapamycin induced cell cycle arrest in proliferating B-CLL cells and inhibited phosphorylation of
p70s6 kinase (p70s6k). In contrast to previous reports on
nonmalignant B cells, the expression of the cell cycle inhibitor p27
was not changed in rapamycin-treated leukemic cells. Treatment
with rapamycin prevented retinoblastoma protein (RB) phosphorylation in
B-CLL cells without affecting the expression of cyclin D2, but cyclin
D3 was no longer detectable in rapamycin-treated B-CLL cells.
In addition, rapamycin treatment inhibited cyclin-dependent
kinase 2 activity by preventing up-regulation of cyclin E and cyclin A. Interestingly, survivin, which is expressed in the proliferation
centers of B-CLL patients in vivo, is not up-regulated in
rapamycin-treated cells. Therefore, rapamycin interferes with the
expression of many critical molecules for cell cycle regulation in
cycling B-CLL cells. We conclude from our study that rapamycin might be
an attractive substance for therapy for B-CLL patients by inducing a
G1 arrest in proliferating tumor cells.
(Blood. 2003;101:278-285) B-cell chronic lymphocytic leukemia (B-CLL) is
characterized by the progressive accumulation of small malignant B
cells, which are arrested in the G0 phase of the cell
cycle.1 In the peripheral blood, B-CLL cells express high
levels of the cell cycle inhibitor p27,2 but B-CLL cells
with low expression of p27 have been identified in so-called
proliferation centers in lymph nodes and bone marrow.3
Interestingly, clusters of survivin and Ki67-positive cells were
observed in the bone marrow and lymph nodes of B-CLL patients,
interspersed with CD3-positive T lymphocytes.4 Survivin is
a member of the family of inhibitors of apoptosis proteins (IAP)5 and is expressed in the G2/M phase of the cell
cycle.6 Proliferation of B-CLL cells might be dependent on
the pseudofollicle microenvironment,7 where infiltrating
autologous T cells can provide CD40 stimulation and
cytokines.4,8,9,10 These cycling cells are thought to
represent the proliferating compartment of B-CLL and might be important
for disease progression.4 Therefore, effective drugs for
treatment of this still-incurable disease should be targeted against
the proliferating pool rather than the accumulating pool of cells.
However, B-CLL cells separated from the peripheral blood display a
marked hyporesponsiveness to a variety of polyclonal B-cell
activators.11,12 Thus, the effect of chemotherapeutic
agents or cell cycle inhibitors on cycling cells has not been
investigated in B-CLL. However, normal and malignant B cells are highly
susceptible to stimulation with immunostimulatory CpG-oligonucleotides
(ODN).13-15
We have previously shown that a high percentage of B-CLL cells traverse
the cell cycle upon stimulation with CpG-ODN and
interleukin-216 (IL-2) and have investigated the
expression of the cyclin-dependent kinase (cdk) inhibitor p27, cyclin
D2, and cyclin D3 in this in vitro model of cycling B-CLL
cells.17
Rapamycin is a streptomyces derivative that modulates signal
transduction pathways that link mitogenic stimuli to the synthesis of
proteins regulating cell cycle progression.18 Rapamycin is widely used as an immunosuppressant in organ transplant recipients and
has shown limited toxicities even in combination schedules with other
immunosuppressants like cyclosporine or
corticosteroids.19,20 The intracellular rapamycin receptor
is a small protein termed FKBP12 (FK506-binding
protein).21 The FKBP-rapamycin complex inhibits the
function of a serine/threonine kinase, mTOR (mammalian target of
rapamycin), thereby blocking stimulation of the ribosomal s6 kinase
p70s6 kinase (p70s6k). P70s6k in turn
phosphorylates the 40s ribosomal protein S6, which favors translation
of mRNAs that encode ribosomal proteins and elongation factors.18,22 Another target of mTOR is a
low-molecular-weight repressor of translation initiation termed
phosphorylated heat- and acid-stable protein regulated by insulin
(PHAS-I). Phosphorylation of PHAS-I results in its dissociation
from eukaryotic initiation factor (eIF)-4E and increases
eIF-4E-dependent translation initiation.23,24
While the potential of rapamycin varies between different cell
types,18 it has been reported to inhibit cell cycle
progression in a variety of cell types, including human T cells and B
cells.25,26 In addition, rapamycin has in vitro and in
vivo activity against a broad range of human tumor cell
lines27-29 and is considered to represent a promising new
class of cytostatic anticancer agents.30
In the present study, we have analyzed the effect of rapamycin on cell
cycle progression and expression of cell cycle regulatory molecules in
a model of proliferating B-CLL cells to better define a potential role
for this drug in therapy of B-CLL patients.
Cell samples
Reagents and antibodies
Separation procedures Peripheral blood mononuclear cells (PBMNCs) were isolated from heparinized blood samples by centrifugation over a Ficoll-Hypaque layer (Biochrom, Berlin, Germany) of 1.077 g/mL density. For separation of CLL-B cells, PBMNCs were incubated with anti-CD2 and anti-CD14 magnetic beads (Dynabeads M450; Dynal, Oslo, Norway) according to the manufacturer's instructions. Such prepared B cells from CLL patients were more than 98% pure as assessed by direct immunofluorescence using a Coulter Epics XL (Coulter, Hamburg, Germany). Purification of tonsillar B-cell fraction was performed by negative selection as described for CLL-B cells.Culture conditions Purified normal and leukemic B cells were cultured in RPMI 1640 medium (Biochrom) supplemented with 10% fetal calf serum (Biochrom); penicillin/streptomycin, 50 IU/mL; Na-pyruvate, 1 mM; L-glutamine, 2 mM; L-asparagine, 20 µg/mL; 2-mercaptoethanol, 0.05 mM; HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), 10 mM; and minimum essential medium (MEM) nonessential amino acids, 0.7 × (Biochrom) at 37°C and 5% CO2 in a fully humidified atmosphere in 12-well plates at 5 × 106 cells in a total volume of 5 mL. HeLa cells stably expressing the CD40 ligand (CD40LH) were kindly provided by C. Wendtner, Medical Clinic III, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich.[3H]-thymidine uptake Purified B cells were cultured at 105 cells/200 µL in round-bottom wells with or without DSP30 at 1 µM and IL-2 (100 U/mL) for induction of B-cell proliferation. For CD40 ligand-induced activation, CD40LH cells were irradiated (10 000 rad), plated at 104 cells/well in flat-bottom wells, and incubated overnight. Then, 105 B-CLL cells were added, and coculture was performed in a total volume of 200 µL. At the indicated time points, cells were pulsed with [3H]-thymidine (Du Pont, Paris, France) and harvested in a PHD-Cell Harvester (Dunn Labortechnik, Asbach, Germany) after 8 hours. Thymidine incorporation was quantified in a B-counter (Beckmann, Munich, Germany).Cell cycle analysis Approximately 106 cells were collected and fixed overnight in 70% ethanol at 4°C. Cells were then washed and stained with propidium iodide (PI; Sigma) 5 µg/mL in the presence of DNAse-free RNAse (Sigma). After 30 minutes at room temperature, the cells were analyzed via flow cytometry using a Coulter Epics XL cytofluorometer (Hamburg, Germany), acquiring 10 000 events.Immunoblotting A total of 1 to 2 × 107 cells were lysed as previously described17 in lysis buffer (10 mM Tris [tris(hydroxymethyl)aminomethane]-HCL [ph 7.4], 5 mM EDTA [ethylenediaminetetraacetic acid], 130 mM NaCl, 1% Triton, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, and 10 mg/mL each phenantroline, aprotinin, leupeptin, and pepstatin) for 20 minutes at 4°C. Lysates were spun at 12 000 rpm for 20 minutes and supernatant collected. Protein concentration was assessed by the Bio-Rad assay method (Bio-Rad Laboratories, Munich, Germany). Total extracts (50 µg/lane) were subjected to 12% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) (7.5% for detection of the RB protein, 10% for detection of p70s6 kinase), and blotting was performed on polyvinylidenefluoride membranes (Immobilon-P; Millipore GmbH, Bedford, MA). Blots were developed using SuperSignal chemoluminescent substrates from Pierce Chemical Company (KMF GmbH, Sankt Augustin, Germany). To control for equal protein loading, amido black staining was performed (data not shown).In vitro kinase assay For RB kinase assays, whole-cell extracts were prepared by resuspending the cells on ice in Tween 20 lysis buffer, 50 mM HEPES (ph 7.5 150 mM NaCl, 1 mM EDTA [ph 8.0], 2.5 mM EGTA [ethyleneglycoltetraacetic acid] [ph 8.0], 0.1% Tween 20, 10% glycerol, 1 mM DTT [dichlorodiphenyltrichloroethane], 1 mM NaF, 0.1 mM Na3VO4, and 10 mg/mL of each phenantroline, aprotinin, leupeptin, and pepstatin). Cell lysates were precleared by incubation with a polyclonal rabbit anti-mouse antibody and protein A-Sepharose. Immunoprecipitation of cyclin E and cdk2 complexes was performed as described previously.17 After washing 2 times in Tween 20 lysis buffer, once in Tween lysis buffer containing 500 mM NaCl, once in H20, and 3 times in kinase buffer, 50 mM HEPES (ph 7.5 10 mM MgCL2, 1 mM DTT, 2 mM EGTA, 1 mM NaF, 0.1 mM Na3VO4, 10 mM -glycerophosphat), the reaction was started in 25 µL kinase buffer
containing 20 µmol/L adenosine triphosphate (ATP), 0.5 µg
histone H1 (Upstate Biotechnology, Lake Placid, NY), 10 µCi (0.37 MBq)  32P ATP (5000 Ci [185 000 GBq]/mmol; Amersham,
Freiburg, Germany). After 30 minutes at 30°C, the reaction
was terminated by boiling the samples in 2× SDS sample buffer for 10 minutes. The phosphorylated substrate was then identified by resolution
in 10% SDS-PAGE followed by drying and autoradiography.
Flow cytometric analysis of apoptosis To determine apoptosis-associated parameters, purified B cells were cultured either in medium alone or together with DSP30 (1 µM) and IL-2 (100 U/mL) with or without rapamycin at 50 ng/mL. The samples were washed with phosphate buffered saline (PBS) and resuspended in 500 µL binding buffer (Annexin V-FITC Kit; Immunotech, Marseille, France), containing 1 µL of annexin V-fluorescein isothiocyanate (FITC) stock and 5 µL of 20 µg/mL PI for determination of phosphatidylserine (PS) exposure on the outer plasma membrane. After incubation for 10 minutes at room temperature in a light-protected area, the specimens were quantified by flow cytometry using a Coulter Epics XL cytofluorometer, acquiring 5000 events. Viable cells were annexin V- and PI-negative.DNA fragmentation assay To identify fragmented DNA, a terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay was performed and assessed by cytometry (Boehringer Mannheim, Indianapolis, IN). Then, 106 cells per sample were washed in PBS and fixed in 2% paraformaldehyde for 30 minutes at room temperature. After fixation, the cells were washed twice in PBS containing 0.01% bovine serum albumin and resuspended in TUNEL reaction mixture containing fluorescein dUTP. Fluorescein incorporated in DNA strand breaks was detected by flow cytometry.
Rapamycin induces G1 arrest in cycling B-CLL cells The effect of rapamycin on cycling B-CLL cells was investigated in B-CLL cells activated with the CpG-ODN DSP30 and IL-2. Rapamycin was added at concentrations ranging from 0.5 to 50 ng/mL to activated B-CLL cells. After 72 hours, thymidine incorporation was strongly reduced in B-CLL cells cocultured with rapamycin in concentrations above 1 ng/mL, and maximal suppression was observed at concentrations above 10 ng/mL. One representative experiment of 3 performed is demonstrated in Figure 1A. In addition, we observed a near to complete inhibition of thymidine incorporation in 13 different patient samples using rapamycin at a concentration of 50 ng/mL (Figure 1B). The patient characteristics are provided in Table 1.
Inhibition of cell cycle progression also could be observed when
rapamycin was added at a later time point, but maximal suppression of
thymidine incorporation was noted at higher concentrations (Figure 1C).
To further investigate the effect of rapamycin on cycling B-CLL cells,
PI stains were performed in 3 independent samples. One representative
example is depicted in Figure 2.
While nearly all cells were arrested in the
G0/G1 phase after culture in medium alone,
stimulation with DSP30 and IL-2 caused a significant entry of B-CLL
cells into the cell cycle with a large fraction of cells in the S/G2/M
phase. However, addition of rapamycin induced a complete G1
arrest in these activated B-CLL cells (Figure 2). We confirmed our
results in a coculture system with CD40 ligand expressing HeLa cells
(CD40LH cells) in 3 independent samples. In line with previous
results,12 CD40 ligation alone was not sufficient to
induce strong proliferation in 2 of 3 B-CLL samples. Therefore, we also
stimulated B-CLL cells with CD40LH, IL-2 (100 U/mL), and IL-10 (1 ng/mL), a combination known to provide maximal stimulation for B-CLL
cells.31 Table 2 shows the
results of a thymidine assay that was performed with 3 different
samples. Importantly, rapamycin was able to inhibit the proliferation
induced by CD40LH alone or by the combination of CD40LH, IL-2, and
IL-10. Rapamycin also inhibited DSP30-IL-2-induced proliferation in
cells from these patients (Table 2).
Purified B-CLL cells 105 were cultured in medium alone or in the presence of 104 irradiated HeLa cells stably expressing the cd40 ligand (CD40LH), IL-2 (100 U/mL), IL-10 (1 ng/mL), or rapamycin (Rap) (50 ng/mL), as indicated. After 120 hours, thymidine was added for an additional 8 hours of culture, and thymidine incorporation was assessed as described in "Patients, materials, and methods." In an independent experiment, cells from the same patients were cultured with DSP30 and IL-2 with or without rapamycin for 72 hours, and thymidine incorporation was quantified as described in "Patients, materials, and methods." Rapamycin inhibits p70s6 kinase phosphorylation in B-CLL cells stimulated with DSP30 and IL-2 Treatment of lymphoid or nonlymphoid cells with rapamycin virtually abrogates the activation of p70s6 kinase by a diversity of mitogenic stimuli, but other mechanisms might be involved.18 To date, activation of the p70s6k has not been described in B-CLL. Phosphorylation of p70 threonin 389 is closely associated with kinase activity.32 Therefore, we analyzed phosphorylation of p70s6k in B-CLL cells stimulated with DSP30 and IL-2 with or without rapamycin using an mAb specific for p70s6k phosphorylated at threonin 389. As a positive and negative control, we included total cellular extracts from 293 cells cultured with serum (positive control) or without serum (negative control). While low levels of phosphorylation were observed at early time points, phosphorylation increased after 12 and 24 hours of stimulation and could be completely inhibited by rapamycin (Figure 3).
Analysis of proteins regulating early G1 progression in cycling B-CLL cells in response to rapamycin We have previously demonstrated that G1 progression in B-CLL cells is controlled by cyclin D2, cyclin D3, the cdk inhibitor p27, and cdk4.17 To determine whether rapamycin affected the expression of cyclin D2, cyclin D3, cdk4, or the cdk inhibitor p27, total cell lysates were subjected to Western blotting after 24 to 72 hours of culture in the presence of DSP30 and IL-2 with or without rapamycin. The time kinetics of thymidine incorporation over a period of 72 hours also are provided in Figure 4A. In contrast to normal tonsillar B cells (Figure 4D), p27 levels were not restored to baseline levels but remained undetectable in rapamycin-treated B-CLL cells. Up-regulation of cyclin D2, which is strongly expressed in activated B-CLL cells, was not affected but seemed to be rather prolonged, with a stronger expression after 72 hours of culture. In contrast, cyclin D3 expression was not detectable when cells were cultured in the presence of rapamycin. The expression of cdk4, which is the catalytic partner of cyclin D2 and cyclin D3 in B-CLL cells, and cdk6 were not significantly changed in rapamycin-treated cells (Figure 4B). In line with the proliferation data, RB phosphorylation was diminished in these cells, although expression was slightly increased (Figure 4C).
Analysis of proteins regulating late G1 progression and G1/S transition in cycling B-CLL cells in response to rapamycin Expression of cyclin E, cyclin A, and cdk2, which regulate G1 progression and the G1/S transition in normal and malignant cells,33 has not been described in proliferating B-CLL cells so far. Cdk 2 and cyclin E were both expressed in nonstimulated B-CLL cells. While cdk2 was regulated only slightly upon stimulation with DSP30 and IL-2, cyclin E expression was strongly increased in activated cells. However, up-regulation of cyclin E was not observed in rapamycin-treated B-CLL cells. In addition, cyclin A, which is not only involved in G1/S phase transition but also in S phase progression,34 was expressed at later time points in proliferating B-CLL cells, but cyclin A expression was not observed in rapamycin-treated cells (Figure 5A). To further examine whether reduced levels of cyclin E and cyclin A were associated with reduced kinase activity, we performed in vitro histone H1 kinase assays with cdk2 immunoprecipitates. In vitro cdk2 kinase activity could be detected after 48 hours in activated B-CLL cells and peaked at 72 hours. We included cdk2 immunoprecipitates from proliferating and serum-starved raji-lymphoma cells as positive and negative controls, respectively. Corresponding to the reduced cyclin E and cyclin A expression, in vitro cdk2 kinase activity was reduced to baseline levels in B-CLL cells that were cultured in the presence of rapamycin (Figure 5B).
Rapamycin prevents up-regulation of survivin in activated B-CLL cells Survivin is a member of the family of inhibitor of apoptosis proteins5 and interfaces cell cycle progression and apoptosis.6 A prominent role in the pathophysiology of B-CLL has been described recently when survivin was found to be expressed in proliferation centers in lymph nodes and bone marrow.4 Therefore, we analyzed the expression of survivin using Western blots in activated B-CLL cells and B-CLL cells treated with rapamycin. In 3 samples tested, we observed no baseline survivin expression, but strong expression was noted in B-CLL cells stimulated with CpG-ODN and IL-2 after 72 hours of activation. Survivin could not be detected when B-CLL cells were cultured in the presence of rapamycin at 50 ng/mL. One representative experiment is shown in Figure 6.
Rapamycin does not affect apoptosis in cycling or resting B-CLL cells Rapamycin is a potent inducer of G1 arrest in cycling B-CLL cells. Its potential to induce or prevent apoptosis remains controversial.18,26-29 Although rapamycin's mode of action is thought to be cytostatic and not cytotoxic,30 a G1 arrest in the proliferating compartment of B-CLL cells might theoretically result in decreased apoptosis. This would be a strong argument against rapamycin as a new drug for B-CLL patients. Therefore, we analyzed the effect of rapamycin on apoptosis of activated and resting B-CLL cells and performed annexin V assays after 48 and 72 hours in B-CLL cells cultured in medium alone or with DSP30 and IL-2 (stimulated/activated). The mean percentages of viable cells (annexin and PI negative) from 5 independent experiments are shown in Figure 7A. We confirmed our results with TUNEL staining in 2 different samples, which demonstrated a slight increase of DNA degradation. One experiment is shown in Figure 7B. Therefore, rapamycin has only limited effects on apoptosis in cycling or resting B-CLL cells.
B-CLL cells are arrested in G0 phase of the cell cycle1 and demonstrate a marked hyporesponsiveness to a variety of polyclonal B-cell activators.11,12 However, strong proliferative responses can be induced in T-cell B-CLL cocultures9,10 or in the presence of CD40 ligand-transfected cell lines together with IL-2 and IL-10.31 These proliferative signals can be derived from infiltrating T helper cells,8,9,10 which are part of the microenvironment of B-CLL proliferation centers in vivo.4,7 Cycling B-CLL cells from this proliferating compartment might feed the pool of small resting B-CLL cells in the accumulating compartment.4 These cells have been described to express survivin and Ki-674 and display decreased expression of the cdk inhibitor p27.3 We recently have described an in vitro model of proliferating B-CLL cells that allows investigation of cell cycle regulatory proteins in the absence of "contaminating" T cells or HeLa cells.16 A high percentage of B-CLL cells traverse the cell cycle upon stimulation with CpG-ODN and IL-2, and G1 progression is controlled by cyclin D2, cyclin D3, p27, and cdk4.17 Rapamycin and its derivative, CCI-779, are considered to represent a new class of "cytostatic" anticancer agents.30 These substances have displayed in vitro and in vivo activity against a large range of solid tumors and lymphomas,28-30,35,36 and CCI-779 is currently being tested in phase 1 clinical trials.37 Phosphatase and tensin homolog deleted on chromosome 10 (PTEN)-deficient tumors and tumors with constitutively activated akt kinase or p70s6 kinase seemed to be especially susceptible to rapamycin treatment.38-40 P70s6 kinase function is essential for G1 progression by regulating the translation of a subset of mRNAs whose protein products are required for progression through the G1 phase of the cell cycle.41,42 As expected, rapamycin did not affect cell cycle distribution of resting B-CLL cells (Figure 2). However, addition of rapamycin caused a dose-dependent inhibition of thymidine incorporation in B-CLL cells activated with CpG-ODN DSP30 and IL-2 (Figure 1A). At a concentration of 50 ng/mL, a near to complete inhibition of proliferation was observed in 13 different B-CLL samples (Figure 1B, P < .001). PI stains confirmed that rapamycin caused a G1 arrest in activated B-CLL cells (Figure 2). Importantly, cell cycle arrest also occurred after delayed addition of rapamycin to the cultures. We were able to confirm the results of our in vitro model in B-CLL cells activated with CD40LH with or without IL-2 and IL-10 (Table 2). CD40 ligand, IL-2, and IL-10 are considered to be in vivo proliferation signals provided by autologous T cells.7 However, stimulation with CpG-ODN and IL-2 was more reliable and allowed us to perform analysis of cell cycle regulatory proteins in the absence of "contaminating" HeLa cells. Because rapamycin exerts much of its activities through inhibition of p70S6k phosphorylation18,22 and p70S6k recently has been reported to regulate cell cycle progression in human B cells,43 we analyzed phosphorylation of p70S6k in B-CLL cells activated with DSP30 and IL-2. We observed Thr 389 phosphorylation of p70S6k in B-CLL cells upon activation with DSP30 and IL-2 that could be inhibited by rapamycin (Figure 3). Phosphorylation peaked at late time points, which might be explained by the formation of IL-2 high-affinity receptors upon stimulation with DSP3022 and subsequent IL-2 signaling events. Rapamycin can block G1 to S-phase transition in a number of cell types by blocking growth factor-stimulated elimination of the cdk inhibitor p27.26,33,44 In contrast to our findings in tonsillar B cells, we observed no up-regulation of p27 in rapamycin-treated B-CLL cells (Figure 4). Therefore, we went on to analyze the expression of cyclin D2, cyclin D3, cyclin E, and cyclin A, which are important for regulating progression through the G1 phase and transition from the G1 to S phase of the cell cycle.34 Treatment with rapamycin prevented RB phosphorylation in B-CLL cells without affecting the expression of cyclin D2, but cyclin D3 was no longer detectable in rapamycin-treated B-CLL cells (Figure 4). Although expression of early D-type cyclins was not influenced by rapamycin in activated T cells,45 rapamycin caused cyclin D3 down-regulation in a breast cancer cell line and in primary cultures of spermatogonia,46,47 suggesting that cyclin D3 expression is differentially regulated in different cell types. In mid to late G1, cdk2-cyclin E and cdk2-cyclin A are sequentially activated and are needed for complete phosphorylation of RB.34,48 In addition to the inhibition of cyclin D3 up-regulation, we observed a striking effect of rapamycin on the expression of cyclin E and cyclin A, which resulted in a reduction of cdk2 kinase activity to baseline values (Figure 5A-B). Depending on the cell type, cyclin E expression was reported to be inhibited by rapamycin or not in previous studies.49,50 Cyclin A also has been described to be down-regulated by rapamycin treatment,26,50 but the observed reduced expression might also be a consequence of RB inactivation.51 Therefore, rapamycin inhibits cell cycle progression by targeting cyclin D3, cyclin A, and cyclin E, which are all required for entry into S phase.34 Recently, survivin, which is a member of the IAP family of proteins,4 was demonstrated to be expressed in cycling B-CLL cells in proliferation centers in vivo, and survivin expression was induced in vitro upon CD40 stimulation.4 It was postulated that survivin expression is important in the pathophysiology of B-CLL by interfacing proliferation and apoptosis.6 Therefore, targeting survivin expression is a promising approach in tumor therapy.52-54 Regulation of survivin expression by rapamycin has not been reported so far, but we observed a complete inhibition of survivin expression in rapamycin-treated cells (Figure 6). Suppression of survivin expression in cycling B-CLL adds to the powerful effects of rapamycin treatment on cycling B-CLL cells. Rapamycin failed to significantly enhance the percentage of cells undergoing apoptosis in cycling or resting B-CLL cells (Figure 7). However, imatinib mesylate (Gleevec), which is the most successful example for targeted therapy,55 also acts by inhibiting proliferation rather than by inducing apoptosis.55,56 We are currently investigating whether rapamycin sensitizes cycling B-CLL cells to apoptosis induced by chemotherapeutic drugs, as has been reported in lymphoblastoid cells.57 The inhibitory effect of rapamycin on cycling B-CLL cells might be exploited therapeutically because activated B-CLL cells can be identified in the proliferation centers of lymph nodes, bone marrow, and the spleen and contribute to disease progression.3,4 In addition, the inhibitory effect of rapamycin on activated T cells, which might provide survival signals in proliferation centers,7-10 is well documented and might contribute to a therapeutic effect.26 Rapamycin might also reduce angiogenesis in the bone marrow by interfering with vascular endothelial growth factor (VEGF) signaling.58 Increased angiogenesis and VEGF production both have been implicated in B-CLL pathophysiology.59,60 Rapamycin is widely used as an immunosuppressant in solid-organ transplant recipients with limited side effects, even in combination schedules.19,20 In addition, it has demonstrated a great potential to inhibit stent restenosis in patients with coronary heart disease.61 Pharmacologic studies have revealed that plasma levels above 15 ng/mL are easily achievable and were well tolerated in patients treated with rapamycin.62 This is important in view of the strong inhibitory effect of rapamycin on proliferating B-CLL cells at concentrations above 5 ng/mL (Figure 1A). Because relapse seems to be inevitable in B-CLL cells even after complete remissions have been achieved,63 a maintenance therapy with rapamycin might be of value in delaying time to tumor progression, especially in patients at high risk for disease progression. Such a treatment schedule might not only be able to improve survival but might also strongly improve patients' quality of life. The potential for long-term therapy with rapamycin and its analog CCI-779 has been recognized recently in cancer patients,64 and phase 1/2 studies of CCI-779 in cancer patients are currently being performed.37 Therefore, phase 1/2 studies with rapamycin will soon be initiated in patients with B-CLL at our institution. Rapamycin also might be combined with other chemotherapeutic drugs because it was well tolerated in combination with other immunosuppressants and corticosteroids.19,20,62 Further in vitro studies will deal with the effect of combination schedules of chemotherapeutic agents and rapamycin on cycling and resting B-CLL cells.
Supported by a research grant from the Technical University of Munich (KKF H30-97) and a grant from the Deutsche Forschungsgemeinschaft DE 771.
Submitted January 23, 2002; accepted August 1, 2002. Prepublished online as Blood First Edition Paper, August 29, 2002; DOI 10.1182/blood-2002-01-0189.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Thomas Decker, 3rd Department of Medicine, Technical University of Munich, Ismaninger Str 15, 81675 Munich, Germany; e-mail: t.decker{at}lrz.tu-muenchen.de.
1. Meinhardt G, Wendtner CM, Hallek M. Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. J Mol Med. 1999;77:282-293[CrossRef][Medline] [Order article via Infotrieve].
2.
Vrhovac R, Delmer A, Tang R, Marie JP, Zittuon R, Ajchenbaum-Cymbalista F.
Prognostic significance of the cell cycle inhibitor p27 in chronic B-cell lymphocytic leukemia.
Blood.
1998;91:4694-4700
3.
Qintanilla-Martinez LC, Thieblemont S, Fend F, et al.
Mantle cell lymphoma lack expression of p27kip1, a cyclin-dependent kinase inhibitor.
Am J Pathol.
1998;153:175-182
4.
Granziero L, Ghia P, Circosta P, et al.
Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia.
Blood.
2001;97:2777-2783 5. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921[CrossRef][Medline] [Order article via Infotrieve]. 6. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580-584[CrossRef][Medline] [Order article via Infotrieve].
7.
Caligaris-Cappio F, Hamblin TJ.
B-cell chronic lymphocytic leukemia: a bird of a different feather.
J Clin Oncol.
1999;17:399-408
8.
Decker T, Flohr T, Trautmann P, et al.
Role of accessory cells in cytokine production by T cells in chronic B-cell lymphocytic leukemia.
Blood.
1995;86:1115-1123 9. Tretter T, Brass U, Schuler M, et al. Direct cellular interaction with activated CD4+ T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro. Cell Immunol. 1998;189:41-50[CrossRef][Medline] [Order article via Infotrieve].
10.
Ranheim EA, Kipps TJ.
Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal.
J Exp Med.
1993;177:925-935
11.
Lankester AC, van Schijndel GM, van der Schoot CE, van Oers MH, van Noesel CJ, van Lier RA.
Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells.
Blood.
1995;86:1090-1097
12.
Fluckiger AC, Rossi JF, Bussel A, Bryon P, Bancherau J, Defrance T.
Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors.
Blood.
1992;80:3173-3181 13. Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky P. Activation of human B cells by phosphorothioate oligonucleotides. J Clin Invest. 1996;98:1119-1129[Medline] [Order article via Infotrieve].
14.
Hartmann G, Krieg AM.
Mechanism and function of a newly identified CpG DNA motif in human primary B cells.
J Immunol.
2000;164:944-953
15.
Decker T, Schneller F, Sparwasser T, et al.
Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine secretion and an immunogenic phenotype in B-CLL patients.
Blood.
2000;95:999-1006 16. Decker T, Schneller F, Kronschnabl M, et al. Immunostimulatory CpG-oligonucleotides induce the expression of functional IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol. 2000;28:558-568[CrossRef][Medline] [Order article via Infotrieve]. 17. Decker T, Schneller F, Hipp S, et al. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia. 2002;16:327-334[CrossRef][Medline] [Order article via Infotrieve]. 18. Abraham RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol. 1998;10:330-336[CrossRef][Medline] [Order article via Infotrieve]. 19. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolismus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001;71:271-280[CrossRef][Medline] [Order article via Infotrieve].
20.
Kahan BD.
Efficacy of sirolismus compared with azathioprine for reduction of acute renal allograft rejection 21. Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature. 1989;341:755-757[CrossRef][Medline] [Order article via Infotrieve]. 22. Jefferies HBJ, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5' TOP mRNA translation through inhibition of p70s6k. Embo J. 1997;16:3693-3704[CrossRef][Medline] [Order article via Infotrieve].
23.
Raught B, Gingras AC, Sonnenberg N.
The target of rapamycin (TOR) proteins.
Proc Natl Acad Sci U S A.
2001;98:7037-7044
24.
Gingras AC, Gygi SP, Raught B, et al.
Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism.
Genes Dev.
1999;13:1422-1437 25. Wicker SL, Boltz RC, Matt V, Nichols EA, Peterson LB, Sigal NH. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. Eur J Immunol. 1990;20:2277-2283[Medline] [Order article via Infotrieve].
26.
Kawamata S, Sakaida H, Toshiyuki H, Maeda M, Uchiyama T.
The up-regulation of p27kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines.
Blood.
1998;91:561-569 27. Shi Y, Frankel A, Radvanyi AG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res. 1996;55:1982-1988.
28.
Seufferlein T, Rozengurt E.
Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells.
Cancer Res.
1996;56:3895-3897
29.
Hosoi H, Dilling MB, Shikata T, et al.
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
Cancer Res.
1999;59:886-894
30.
Garber K.
Rapamycin's resurrection: a new way to target the cancer cell cycle.
J Natl Cancer Institute.
2001;93:1517-1519
31.
Fluckiger AC, Garrone P, Durand I, Galizzi JP, Bancherau J.
Interleukin 10 (IL-10) upregulates functional high affinity receptors on normal and leukemic B lymphocytes.
J Exp Med.
1993;178:1473-1481 32. Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res. 1999;253:100-109[CrossRef][Medline] [Order article via Infotrieve].
33.
Wagner EF, Hleb M, Hanna N, Sharma S.
A pivotal role of cyclin D3 and cyclin-dependent kinase inhibitor p27 in the regulation of IL-2, IL-4- or IL-10-mediated human B cell proliferation.
J Immunol.
1998;161:1123-1131
34.
Sherr CJ.
Cancer cell cycles.
Science.
1996;274:1672-1677 35. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation. 1995;60:264-270[Medline] [Order article via Infotrieve].
36.
Geoerger B, Kerr K, Tang CB, et al.
Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.
Cancer Res.
2001;61:1527-1532 37. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000;19:6680-6686[CrossRef][Medline] [Order article via Infotrieve].
38.
Neshat MS, Mellinghoff IK, Tran C, et al.
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Proc Natl Acad Sci U S A.
2001;98:10314-10319
39.
Podsypanina K, Lee RT, Politis C, et al.
An inhibitor of mTOR reduces neoplasia and normalizes p70s6 kinase activity in Pten ± mice.
Proc Natl Acad Sci U S A.
2001;98:10031-10033
40.
Grewe M, Gansauge F, Schmidt RM, Adler G, Seufferlein T.
Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6k pathway in human pancreatic cancer cells.
Cancer Research.
1999;59:3581-3587 41. Brown EJ, Schreiner SL. A signaling pathway to translational control. Cell. 1996;86:517-520[CrossRef][Medline] [Order article via Infotrieve]. 42. Jefferies HBJ, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5' TOP mRNA translation through inhibition of p70s6k. Embo J. 1997;16:3693-3704[CrossRef][Medline] [Order article via Infotrieve].
43.
Li HL, Davis W, Pure E.
Suboptimal cross-linking of antigen receptor induces Syk-dependent activation ofp70S6 kinase through protein kinase C and phosphoinositol 3 kinase.
J Biol Chem.
1999;274:9812-9820 44. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994;372:570-573[CrossRef][Medline] [Order article via Infotrieve].
45.
Turner JM.
IL-2-dependent induction of G1 cyclins in primary T cells is not blocked by rapamycin or cyclosporin A.
Int Immunol.
1993;5:1199-1209
46.
Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis EN, Rosen N.
Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway.
J Biol Chem.
1998;273:29864-29872
47.
Feng LX, Ravindranath N, Dym M.
Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia.
J Biol Chem.
2000;275:25572-25576
48.
Lundberg AS, Weinberg RA.
Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes.
Mol Cell Biol.
1998;18:753-761
49.
Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ.
P53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.
Cancer Res.
2001;61:3373-3381
50.
Morice WG, Wiederrecht G, Brunn GJ, Siekierka JJ, Abraham RT.
Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes.
J Biol Chem.
1993;268:22737-22745
51.
Knudsen KE, Fribourg AF, Strobeck MW, Blanchard JM, Knudsen ES.
Cyclin A is a functional target of retinoblastoma tumor suppressor protein-mediated cell cycle arrest.
J Biol Chem.
1999;274:27632-27641
52.
Kanwar JR, Shen WP, Rupinder KK, Berg RW, Krissansen GW.
Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy.
J Natl Cancer Inst.
2001;93:1541-1552 53. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest. 2001;108:981-990[CrossRef][Medline] [Order article via Infotrieve]. 54. Reed JC. The survivin saga goes in vivo. J Clin Invest. 2001;108:965-969[Medline] [Order article via Infotrieve]. 55. Druker BJ, Lydon BN. Lessons learned from the development of an Abl tyrosine inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3-7[Medline] [Order article via Infotrieve].
56.
Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R.
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.
Blood.
2002;99:3792-3800 57. Ishizuka T, Sakata N, Johnson GL, Gelfand EW, Terada N. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits Jnk activity in lymphoblastoid cells. Biochem Biophys Res Com. 1997;230:386-391[CrossRef][Medline] [Order article via Infotrieve]. 58. Guna M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128-135[CrossRef][Medline] [Order article via Infotrieve].
59.
Chen H, Treweeke AT, West DC, et al.
In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells.
Blood.
2000;96:3181-3187
60.
Aguayo A, O'Brian S, Keating M, et al.
Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia.
Blood.
2000;96:768-770
61.
Marx SO, Marks AR.
Bench to bedside: the development of rapamycin and its application to stent restenosis.
Circulation.
2001;104:852-855
62.
Groth CG, Backman L, Morales JM, et al.
Sirolismus (rapamycin)-based therapy in human renal transplantation
63.
Pavletic ZS, Bierman PJ, Vos JM.
High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma.
Ann Oncol.
1998;9:1023-1026
64.
Mills GB, Lu Y, Kohn EC.
Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.
Proc Natl Acad Sci U S A.
2001;98:10031-10033
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  C. R. Geest, F. J. Zwartkruis, E. Vellenga, P. J. Coffer, and M. Buitenhuis Mammalian target of rapamycin activity is required for expansion of CD34+ hematopoietic progenitor cells Haematologica, July 1, 2009; 94(7): 901 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Zhao, A. Auerbach, A. M. D'Costa, A. P. Rapoport, A. M. Burger, E. A. Sausville, S. A. Stass, F. Jiang, A. M. Sands, N. Aguilera, et al. Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy Clin. Cancer Res., March 1, 2009; 15(5): 1708 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Hartford, A. A. Desai, L. Janisch, T. Karrison, V. M. Rivera, L. Berk, J. W. Loewy, H. Kindler, W. M. Stadler, H. L. Knowles, et al. A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies Clin. Cancer Res., February 15, 2009; 15(4): 1428 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Armand, S. Gannamaneni, H. T. Kim, C. S. Cutler, V. T. Ho, J. Koreth, E. P. Alyea, A. S. LaCasce, E. D. Jacobsen, D. C. Fisher, et al. Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning J. Clin. Oncol., December 10, 2008; 26(35): 5767 - 5774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, F. Murray, A. Zahno, J. R. Kanter, D. Chou, R. Suda, M. Fenlon, L. Rassenti, H. Cottam, T. J. Kipps, et al. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia PNAS, December 9, 2008; 105(49): 19532 - 19537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ferri, A. Granata, C. Pirola, F. Torti, P. J. Pfister, R. Dorent, and A. Corsini Fluvastatin Synergistically Improves the Antiproliferative Effect of Everolimus on Rat Smooth Muscle Cells by Altering p27Kip1/Cyclin E Expression Mol. Pharmacol., July 1, 2008; 74(1): 144 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gridelli, P. Maione, and A. Rossi The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer Oncologist, February 1, 2008; 13(2): 139 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Gotze, D. Hoffmann, H. M. Schatzl, C. Peschel, F. Fend, and T. Decker Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR Inhibitor for relapsed chronic lymphocytic leukemia Haematologica, September 1, 2007; 92(9): 1282 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Garcia-Morales, E. Hernando, E. Carrasco-Garcia, M. P. Menendez-Gutierrez, M. Saceda, and I. Martinez-Lacaci Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells. Mol. Cancer Ther., September 1, 2006; 5(9): 2172 - 2181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Raslova, V. Baccini, L. Loussaief, B. Comba, J. Larghero, N. Debili, and W. Vainchenker Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation Blood, March 15, 2006; 107(6): 2303 - 2310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Guerriero, I. Parolini, U. Testa, P. Samoggia, E. Petrucci, M. Sargiacomo, C. Chelucci, M. Gabbianelli, and C. Peschle Inhibition of TPO-induced MEK or mTOR activity induces opposite effects on the ploidy of human differentiating megakaryocytes J. Cell Sci., February 15, 2006; 119(4): 744 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Langenfeld, Y. Kong, and J. Langenfeld Bone Morphogenetic Protein-2-Induced Transformation Involves the Activation of Mammalian Target of Rapamycin Mol. Cancer Res., December 1, 2005; 3(12): 679 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Butany, K Carmichael, S W Leong, and M J Collins Coronary artery stents: identification and evaluation J. Clin. Pathol., August 1, 2005; 58(8): 795 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Grund, D. D. Spyropoulos, D. K. Watson, and R. C. Muise-Helmericks Interleukins 2 and 15 Regulate Ets1 Expression via ERK1/2 and MNK1 in Human Natural Killer Cells J. Biol. Chem., February 11, 2005; 280(6): 4772 - 4778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hleb, S. Murphy, E. F. Wagner, N. N. Hanna, N. Sharma, J. Park, X. C. Li, T. B. Strom, J. F. Padbury, Y.-T. Tseng, et al. Evidence for Cyclin D3 as a Novel Target of Rapamycin in Human T Lymphocytes J. Biol. Chem., July 23, 2004; 279(30): 31948 - 31955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Stromberg, A. Dimberg, A. Hammarberg, K. Carlson, A. Osterborg, K. Nilsson, and H. Jernberg-Wiklund Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone Blood, April 15, 2004; 103(8): 3138 - 3147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Decker, M. Oelsner, R. J. Kreitman, G. Salvatore, Q.-c. Wang, I. Pastan, C. Peschel, and T. Licht Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins Blood, April 1, 2004; 103(7): 2718 - 2726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kern, J.-F. Cornuel, C. Billard, R. Tang, D. Rouillard, V. Stenou, T. Defrance, F. Ajchenbaum-Cymbalista, P.-Y. Simonin, S. Feldblum, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway Blood, January 15, 2004; 103(2): 679 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Campagna, P. Beffy, R. Del Carratore, L. Hauri, S. Simi, S. Bonatti, and M. Simili Diethylsulphate and methylnitrosourea affect different targets in Chinese hamster fibroblasts: possible mechanisms of aneuploidy induction by these agents Mutagenesis, September 1, 2003; 18(5): 405 - 410. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
) or after 24 hours of stimulation (
).
Thymidine incorporation was measured after 72 hours as described in
"Patients, materials, and methods." Panel C shows one
representative experiment (means ± SEMs of
triplicates).
a randomized multicentre study: the Rapamune US study group.
Lancet.
2000;356:194-202